<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250317065108N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-04-06</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>"Investigating the Effects of Neuromuscular Electrical Stimulation and Core Training on Hormones and Sports Performance in Men"</public_title>
      <acronym>NMES</acronym>
      <scientific_title>Comparison of the Effects of Neuromuscular Electrical Stimulation and Core Training on Anabolic-Catabolic, Metabolic Hormones, and Sports Performance in Adult Man.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-04-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82645</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: 1.	Simultaneous comparison of two distinct interventions: The study simultaneously compares two intervention methods (core training and NMES) and their combination with a control group.	2.	Four-group design: The study employs a four-group design, including control, core training, neuromuscular electrical stimulation, and the combined group, allowing for a more detailed analysis of independent and combined effects.	3.	8-week intervention duration: The study spans an 8-week intervention period to examine the long-term effects of training and electrical stimulation.	4.	Focus on anabolic and catabolic hormones: The study investigates the effects of training and NMES on anabolic and catabolic hormones, a less common focus in similar research.	5.	Assessment of metabolism and physical performance: In addition to hormones, the study evaluates the impact of these interventions on physical performance and metabolic markers.	6.	Body composition assessment with InBody 270: The use of the InBody 270 device for accurate body composition measurement is a unique feature of this study.	7.	Utilization of advanced technology (TruSculpt Flex) for NMES: The use of the advanced TruSculpt Flex device for neuromuscular electrical, Randomization description: Participants will be randomly assigned to one of the four groups (control, core training, neuromuscular electrical stimulation, or combined training and stimulation) using block randomization with equal block sizes. The allocation sequence is not predetermined and will be generated using random number software to ensure balance across groups, Blinding description: In this study, both the outcome assessor and data analyst are blinded to group allocation. While participants and intervention administrators are aware of the assigned groups, the outcome assessor collects performance and metabolic data without knowledge of group assignments. Additionally, the data analyst processes and analyzes the data after collection and coding, ensuring blinding to group allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Prevention.</hc_freetext>
      <i_freetext>Intervention 1: The core training group will perform core stability and strength exercises for 8 weeks, 3 sessions per week. Intervention 2: Intervention group: The NMES group will receive neuromuscular electrical stimulation using the TruSculpt Flex device (2 sessions per week for 3 weeks, plus a reminder session in week 8). Intervention 3: Intervention group: The combined group will receive only NMES in the first 3 weeks and will start core training from week 4. Intervention 4: Control group:  The control group will receive no intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Its release schedule is not yet known.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Khosro Jalali Dehkordi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khorasgan University, Arghavanie St., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8183895153</zip>
        <telephone>+98 81 8389 5183</telephone>
        <email>khosrojalali@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Khosro Jalali Dehkordi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khorasgan University, Arghavanie St.,</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8183895183</zip>
        <telephone>009831335002352</telephone>
        <email>khosrojalali@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gender: Male
Age: 35 to 55 years
Good general health (No chronic metabolic, cardiovascular, or neuromuscular diseases)
No prior regular core training or NMES usage in the past six months
No use of hormonal drugs or metabolism-affecting supplements
Ability to attend study sessions and adhere to the research protocol
No regular alcohol or tobacco consumption</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>55 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Presence of metabolic, cardiovascular, or neuromuscular diseases (e.g., diabetes, heart disease, multiple sclerosis).
Use of hormonal medications or supplements affecting metabolism (e.g., testosterone, steroids, insulin).
History of NMES use in the past six months.
Recent surgeries affecting physical activity or muscle function.
Presence of implantable electronic devices (e.g., pacemakers) that may interfere with NMES.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The core training group will perform core stability and strength exercises for 8 weeks, 3 sessions per week.</i_keyword>
      <i_keyword>Intervention group: The NMES group will receive neuromuscular electrical stimulation using the TruSculpt Flex device (2 sessions per week for 3 weeks, plus a reminder session in week 8).</i_keyword>
      <i_keyword>Intervention group: The combined group will receive only NMES in the first 3 weeks and will start core training from week 4.</i_keyword>
      <i_keyword>Control group:  The control group will receive no intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome variables include changes in anabolic hormones (testosterone, IGF-1, growth hormone), catabolic hormones (cortisol), related metabolic markers (insulin, ALT, AST, alkaline phosphatase), and sports performance indices (muscle strength, endurance, flexibility, step length and time, symmetry, and dynamic stability in gait). These variables will be measured before and after the intervention. Timepoint: The outcome variables will be measured at two time points: before the intervention (Baseline) and after the intervention period (Post-intervention, week 8). Method of measurement: Anabolic and catabolic hormones (testosterone, IGF-1, growth hormone, cortisol, insulin): Blood samples will be collected in a fasting state and analyzed using Chemiluminescent Immunoassay (CLIA). Liver enzymes (ALT, AST) and alkaline phosphatase: Measured using biochemical enzymatic methods، Sports performance:	Muscle strength and endurance using a handheld dynamometer and standard endurance tests. Flexibility using the Sit and Reach Test. Step length, step time, symmetry, and dynamic stability in gait will be assessed using motion analysis and gait assessment systems، Quality of Life Questionnaire (English):To assess quality of life, the Short Form Health Survey (SF-36) will be used. This questionnaire consists of 36 questions evaluating various aspects of physical and mental health.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-12-25</approval_date>
        <contact_name>Ethics Committee on Research Islamic Azad University, Isfahan Branch (Khorasgan)</contact_name>
        <contact_address>Arghavanie blv., Khorasgan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
